Advanced Therapies Day Three

 

Advanced Therapies and Regenerative Medicine Day 3 - Friday 18th May 2018

CRISPR/Cell Line Development

New frontiers in repair and replacement of diseased tissues and organs

CRISPR/Cell Line Development
09:00

CRISPR goes in vivo to make preclinic more predictive

  • Past models in preclinic: what was good and what was bad
  • Application of genome editing for somatic cells engineering: advantages and perspectives
  • The future ahead: overoptimistic vs skeptical visions
09:00

Multipotent adult stem cells: characterization and regeneration 

  •     Unique adult stem cell with unlimited proliferation potential, ability to differentiate into phenotypes of all 3-dermal lineage, does not cause an immune-rejection response
  •     Used in several regeneration models in adult animals, where undifferentiated multipotent adult stem cells differentiate to the phenotypes at the site, thus regenerating the tissue
  •     Human multipotent adult stem cells survive in a rat and differentiate into phenotypes
Paul Lucas, Director of Orthopaedic Research, Department of Orthopaedic Surgery, New York Medical College
CRISPR/Cell Line Development
09:25

CRISPR-mediated genome engineering of CHO cell factories

  • Efficient and controlled genome engineering with CRISPR
  • Isogenic cell line generation and its applications
  • Lessons learned from working with CRISPR
09:25

How the development of tissue therapies can aid the development of functional organ replacements

  • Practical insights into Organovo’s tissue engineering technology that has capabilities working with a variety of cell types
  • Where are there opportunities to collaborate in order to advance developments in using tissue engineering for organ regeneration?
  • Next steps from supplemental tissue therapies towards larger replacement tissues and eventually full organ regeneration
CRISPR/Cell Line Development
09:50

Engineering cells and animals as models for therapies

  • Application of Synthetic Biology approaches  
  • Engineering transgene expression stability in cells and mice
  • Engineering mice as models for therapeutic vaccination
CRISPR/Cell Line Development
10:15

Cell therapy for neurorepair

  • Foetal stem cells are neuroprotective against neonatal hypoxia is he Mia
  • Transplantation reduces brain lesion
  • Mechanisms of action involve adenosine
10:15

Human PSC-derived cardiomyocytes/neurons on 3D micro-tissue devices for matured and functional cell products in drug discovery/cell therapy

  • Importance and needs of more matured/functional/reliable/low-cost cell products from human pluripotent stem cells (hESC/hiPSC) in drug discovery and cell therapy.
  • Robust & low-cost cytokine-free differentiation of cardiomyocytes from human ES/iPS cells by combination of small chemical compounds.
  • Construction of 3D micro-tissue devices with aligned nanofibers for more matured/functional/reliable cardiomyocyte/neuron products.
10:40

Networking refreshment break

Elizabeth Schwarzbach
11:40

Keynote: Harnessing patient data using stem cells to power precision medicine

Elizabeth Schwarzbach, Chief Business Officer, New York Stem Cell Foundation
Dr Yen Choo
12:05

Small molecule drug discovery to selectively stimulate regenerative processes

  • Collaborating with big pharma for successful target discovery
  • Using ATMP knowledge to target and stimulate specific biochemical signalling pathways
  • Use traditional pharmaceutical drug screening technologies to discover synthetic small molecule modulators of regenerative pathways
Dr Michael D West, Ph.D.
12:30

Keynote: What’s new in the field of aging and regeneration?

  • How can molecular and AI technologies help regenerate damaged tissue in humans?
  • What are the current challenges with induced tissue regeneration and how are we tackling them?
  • Combining pluripotent stem cell and iTR technology to form new company AgeX

Networking Lunch

Networking LunchClosing keynotes: What’s next for ATMPs?

Alain Vertes
Dr Frédéric Triebel
14:35

Panel: Combination immunotherapy strategies across pharma and biotech

  • High level pharma companies come together to discuss their strategies for tackling cancer
  • Each company will give a 5-minute presentation on their strategy, and a fire side discussion on oncology focused strategies will follow
  • Strategies will cover cytotherapy, checkpoint inhibitors, combination therapy, sequential therapy, approaches to solid tumours, treatments and diagnostics
Laszlo Radvanyi, Senior Vice President, Senior Scientific Advisor, EMD Serono

End of Day 3

last published: 14/May/18 16:05 GMT

 

DOWNLOAD BROCHURE

 

 

 

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com